rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: A pilot study

Bone Marrow Transplantation

Volumn 35, Issue 9, 2005, Pages 903-907

  Hunault Berger, M ^a   Tanguy Schmidt, A ^a   Rachieru, P ^a   Levy V ^b   Truchan Gracyzk, M ^a   Francois, S ^a   Gardembas Pain, M ^a   Dib, M ^a   Foussard, C ^a   Piard, N ^c   Godon, A ^a   Solal Celigny, P ^d   Ifrah, N ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d CENTRE JEAN BERNARD   (France)

Author keywords

Autologous stem cell transplantation; Erythropoietin; Lymphoma; Multiple myeloma; Red blood cell; Transfusion

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IRON; MELPHALAN; NAVELBINE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; TRANSPLANTATION, AUTOLOGOUS;

EID: 20844447878     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704899     Document Type: Article

References (30)

1. Osterborg A, Brandberg Y, Molostova V et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486-2494.
2. Link H, Boogaerts MA, Fauser AA et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327-3335.
3. Locatelli F, Zecca M, Pedrazzoli P et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994; 13: 403-410.
4. Vannucchi AM, Bosi A, Ieri A et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 1996; 17: 527-531.
5. Chao NJ, Schriber JR, Long GD et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83: 2823-2828.
6. Ayash LJ, Elias A, Hunt M et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 1994; 87: 153-161.
7. Pene R, Appelbaum FR, Fisher L et al. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant 1993; 11: 219-222.
8. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
9. Rodriguez MA, Cabanillas FC, Velasquez W et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-1741.
10. Colombat P, Biron P, Laporte JP et al. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer 1990; 26: 858.
11. Tourani JM, Levy R, Colonna P et al. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol 1992; 10: 1086-1094.
12. Klaesson S, Ringden O, Ljungman P et al. Reduced blood transfusion requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13: 397-402.
13. Biggs JC, Atkinson KA, Booker V et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995; 15: 129-134.
14. Steegmann JL, Lopez J, Otero MJ et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 1992; 10: 541-546.
15. Vannucchi AM, Bosi A, Linari S et al. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study. Haematologica 1997; 82: 53-56.
16. Link H, Brune T, Hubner G et al. Effect of recombinant human erythropoietin after allogenic bone marrow transplantation. Ann Hematol 1993; 67: 169-173.
17. Miller C, Dempsey H, Weiner R et al. Recombinant human erythropoietin (rHuEpo) does not promote 'stem-cell steal' following autologous bone marrow transplant. Blood 1993; 82: 638a.
18. Waller CF, von Lintig F, Daskalakis A et al. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant 1999; 24: 19-24.
19. Ponchio L, Zambelli A, De Stefano A et al. Transfusion requirement can be abolished by epoietin-alpha and autologous platelet predeposit in patients receiving high dose chemotherapy with stem cell support. Haematologica 2000; 85: 219-220.
20. Baron F, Frère P, Fillet G, Beguin Y. Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. Br J Haematol 2003; 123: 103-105.
21. Miller CB, Jones RJ, Zahurak ML et al. Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 1992; 80: 2677-2682.
22. Vannucchi AM, Grossi A, Bosi A et al. Impaired erythropoietin production in mice treated with cyclosporin A. Blood 1991; 78: 1615-1618.
23. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-1994.
24. Johnson CS, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp Hematol 1990; 18: 109-113.
25. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990; 29: 709-713.
26. Zachee P. Controversies in selection of epoetin dosages. Issues and answers. Drugs 1995; 49: 536-547.
27. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol 2002; 9: 93-100.
28. Zermati Y, Garrido C, Amsellem S et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001; 193: 247-254.
29. Beguin Y. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol 1998; 15 (Suppl. 1): S38-S46.
30. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.